Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mirabegron + tolterodine
- Development stage
- Phase 4
- Lead developer
- Astellas Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**mirabegron + tolterodine** is a *combination drug* used to treat overactive bladder (OAB). **Mirabegron** is a β₃-adrenoceptor agonist, while **tolterodine** is a muscarinic receptor antagonist (antimuscarinic). Their combined use targets different pathways in bladder control: mirabegron relaxes the detrusor muscle by stimulating β₃-adrenoceptors, increasing bladder capacity, while tolterodine decreases involuntary bladder contractions by blocking muscarinic receptors. This combination is used for patients with OAB to reduce urinary frequency, urgency, and incontinence, particularly in cases resistant to monotherapy. Clinical and animal studies show the combination can normalize bladder parameters and improve outcomes, potentially with lower risk of anticholinergic side effects compared to higher-dose antimuscarinics alone[2][3].
- Other names
- mirabegron + tolterodine
02
Targets
ADRB3 (β3)CHRM2 (M2)CHRM3 (M3)
Beyond the preview
Go deeper on mirabegron + tolterodine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mirabegron + tolterodine.